We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current GNIIF market cap is 991.88M. The company's latest EPS is JPY 162.2304 and P/E is 0.12.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 7.45B | 9.81B | 12.84B | 18.1B | 26.24B |
| Operating Income | 1.3B | 1.74B | 1.11B | 1.75B | 4.27B |
| Net Income | 181.84M | 1.26B | 1.07B | -1.26B | 8.09B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 20.61B | 23.22B | 30.3B | 33.91B | 62.39B |
| Total Liabilities | 7.51B | 10.45B | 11.03B | 14.1B | 26.34B |
| Total Equity | 13.1B | 12.77B | 19.27B | 19.81B | 36.05B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 788.59M | 1.38B | 552.27M | 393.32M | 6.55B |
| Investing | -153.12M | 570.21M | -260.64M | -4.12B | -6.84B |
| Financing | 2.22B | 801.12M | 2.85B | -646.33M | 10.69B |
| Market Cap | 991.88M |
| Price to Earnings Ratio | 0.12 |
| Price to Sales Ratio | 0.04 |
| Price to Cash Ratio | 0.05 |
| Price to Book Ratio | 0.03 |
| Dividend Yield | - |
| Shares Outstanding | 49.89M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -48.76% |
| 52 Week High | 38.80 |
| 52 Week Low | 19.88 |
| Spread (Intraday) | 1.82 (8.87%) |
| Company Name | GNI Group Ltd (PK) |
| Address |
2-2-2 japan hashimoto-cho chuo, tokyo 103-0023 |
| Website | https://www.gnipharma.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
